Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol
- PMID: 9808595
- DOI: 10.1161/01.cir.98.19.1993
Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol
Abstract
Background: Lipid-lowering secondary-prevention trials of coronary artery disease (CAD) have implicated triglyceride-rich lipoproteins as the main determinants of angiographic progression after elevated LDL cholesterol levels have been lowered with therapy. The present study focuses on the lipoprotein determinants of angiographic CAD progression in men with low HDL cholesterol concentration as their main baseline lipid abnormality who underwent 32 months of randomized therapy with gemfibrozil or placebo.
Methods and results: Men who had undergone coronary bypass surgery (n=372) completed a randomized, placebo-controlled study with gemfibrozil 1200 mg/d. They were selected primarily for HDL cholesterol levels that corresponded to the lowest third for middle-aged men. Average baseline lipid and lipoprotein levels were serum triglyceride, 1.60; serum cholesterol, 5.17; ultracentrifugally separated LDL cholesterol, 3.43; HDL2 cholesterol, 0.41; and HDL3 cholesterol, 0. 61 mmol/L. In the gemfibrozil group, these levels were reduced on average by 40%, 9%, and 6% or increased by 5% and 9%, respectively. On-trial IDL and LDL triglyceride and cholesterol levels significantly predicted global angiographic progression, taking into account changes in native segments and in bypass grafts. HDL3 but not HDL2 cholesterol concentration was associated with protection against progression, especially focal disease in native coronary lesions. VLDL was the lipoprotein most predictive of new lesions in vein grafts; IDL was also significantly related.
Conclusions: This study expands the previous evidence of the triglyceride-rich lipoproteins, especially IDL, as predictors of angiographic progression of CAD but does not negate the significance of mildly elevated LDL levels. Of the HDL subfractions, only HDL3 was protective in this group of men selected for their low initial HDL levels.
Similar articles
-
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.Circulation. 1997 Oct 7;96(7):2137-43. doi: 10.1161/01.cir.96.7.2137. Circulation. 1997. PMID: 9337181 Clinical Trial.
-
Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.Atherosclerosis. 1996 Nov 15;127(1):113-22. doi: 10.1016/s0021-9150(96)05941-2. Atherosclerosis. 1996. PMID: 9006811 Clinical Trial.
-
A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lopid Coronary Angiography Trial.Control Clin Trials. 1997 Feb;18(1):93-119. doi: 10.1016/s0197-2456(96)00091-8. Control Clin Trials. 1997. PMID: 9055055 Clinical Trial.
-
Lipoproteins and coronary heart disease in the Helsinki Heart Study.Eur Heart J. 1990 Dec;11 Suppl H:26-31. doi: 10.1093/eurheartj/11.suppl_h.26. Eur Heart J. 1990. PMID: 2073911 Review.
-
High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.Am J Cardiol. 2000 Dec 21;86(12A):19L-22L. doi: 10.1016/s0002-9149(00)01464-8. Am J Cardiol. 2000. PMID: 11374850 Review.
Cited by
-
Role of fibric acid derivatives in the management of risk factors for coronary heart disease.Drugs. 2004;64(19):2177-98. doi: 10.2165/00003495-200464190-00003. Drugs. 2004. PMID: 15456334 Review.
-
Recent developments in the treatment of hypertriglyceridemia.Curr Atheroscler Rep. 1999 Jul;1(1):31-7. doi: 10.1007/s11883-999-0047-1. Curr Atheroscler Rep. 1999. PMID: 11122689 Review.
-
New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol.Curr Atheroscler Rep. 2001 Sep;3(5):365-72. doi: 10.1007/s11883-001-0074-z. Curr Atheroscler Rep. 2001. PMID: 11487447 Review.
-
High-density lipoprotein cholesterol as a predictor of poor survival in patients with nasopharyngeal carcinoma.Oncotarget. 2016 Jul 12;7(28):42978-42987. doi: 10.18632/oncotarget.7160. Oncotarget. 2016. PMID: 27304186 Free PMC article.
-
High-density lipoprotein subfractions and risk of coronary artery disease.Curr Atheroscler Rep. 2004 Sep;6(5):359-65. doi: 10.1007/s11883-004-0047-0. Curr Atheroscler Rep. 2004. PMID: 15296702 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous